Division of Paratek Pharmaceuticals Inc.
Latest From Novacea Inc.
Genentech pays $725 million upfront for San Diego oncology firm Seragon, and Bluebird adds gene-editing and cell-signaling capabilities by acquiring Precision Genomic Engineering. It was a deal-heavy week ahead of the July 4th Holiday.
Financings Of The Fortnight: Biotech IPO Trends Continue With Supernus’ Offering – Haircuts, Insider Buys
Plus news on recent financing activity by Argos, Telstar, Castlight Health and Transcept.
The University of Oregon in the US has spun out a new company, Cascade ProDrug, and given it exclusive ownership of technology that activates certain prodrugs in oxygen-depleted (hypoxic) tissues.
Transcept Pharmaceuticals is to cut around 30% of its workforce, despite receiving $25 million up front as part of a licensing deal that it signed with Purdue Pharmaceuticals earlier this month.
- Therapeutic Areas
- Novacea Pharmaceuticals Inc.
- D-Novo Therapeutics
- North America
- Parent & Subsidiaries
- Paratek Pharmaceuticals Inc.
- Senior Management
Edward C Albini, VP, CFO
Fong Wang Clow, SVP, Dev.
Edward Schnipper, MD, EVP, CMO
Amar Singh, Chief Commercialization Officer
John G Curd, MD, Pres. & CSO
Karen E Hartwig, VP, Mktg.
- Contact Info
Phone: (650) 228-1800
400 Oyster Blvd.
S. San Francisco, CA 94080
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.